Please ensure Javascript is enabled for purposes of website accessibility

Why Abiomed Shares Are Sinking Today

By Keith Speights - Jan 13, 2020 at 11:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Abiomed's sneak peek at its Q3 results leaves investors underwhelmed.

What happened

Shares of Abiomed (ABMD 2.63%) were sinking 13.8% lower as of 11:15 a.m. EST on Monday. The big decline came after the medical device maker announced preliminary third-quarter revenue of $222 million before the market opened. The consensus Wall Street estimate was for Abiomed to report Q3 revenue of $226.7 million.

So what

One quarter that disappoints analysts isn't the worst thing in the world. However, investors appear to be worried about the reason why Abiomed's revenue was lower than expected. The company said that it "was negatively impacted by two presentations at a conference on November 17, which the company believes are based on misleading analyses."

Human heart with heart wave and hexagon icons in background

Image source: Getty Images.

Those presentations occurred at the American Heart Association (AHA) annual meeting in November. During this meeting, two teams presented data that questioned both the safety and the effectiveness of Abiomed's Impella heart pumps. One presentation stated that Impella is "associated with an increased risk of death, bleeding, and stroke among patients undergoing angioplasty to reopen clogged arteries." Abiomed's share price sank as investors fretted about the potential fallout from the concerns.

Now, there are more worries since the presentations do appear to have taken a toll on sales of Impella. Adding to those worries is that Abiomed updated its fiscal year 2020 revenue guidance to between $846 million and $877 million, down from the previous range of $885 million to $925 million and well below the consensus analysts' revenue estimate of $885.8 million.

Now what

Healthcare stocks can be extremely volatile when there are concerns about the safety or effectiveness of a company's products. The main thing for investors to watch is how the company responds to the situation. In Abiomed's case, the company is taking several positive steps.

Abiomed's medical team reviewed the presentations that alleged safety and efficacy problems with Impella. The company thinks those presentations "are misleading based on older, non-FDA audited, observational data on less than 4% of our patients treated over a 10-year period." Abiomed has launched a major effort to refute the presentations, including selecting physicians who are experts in circulatory support to train other physicians, conducting "a multi-city road show" to support Impella, and working with industry organizations and hospital systems to communicate the results from previous studies of Impella.

CEO Michael Minogue said, "The long-term outlook for Abiomed remains intact and we are working with physician experts to clarify and educate the community on Impella best practice protocols and clinical outcomes." Investors who believe these efforts will be successful should view today's pullback as a buying opportunity.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ABIOMED, Inc. Stock Quote
ABIOMED, Inc.
ABMD
$260.97 (2.63%) $6.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.